Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramucirumab + S-1 + oxaliplatin
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Ramucirumab + S-1 + oxaliplatin (RAM+SOX) is an investigational combination therapy developed for the treatment of advanced gastric cancer and gastroesophageal junction adenocarcinoma. The regimen combines ramucirumab (Cyramza), a fully human IgG1 monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR-2) to inhibit tumor angiogenesis, with the chemotherapy regimen SOX, which consists of S-1 (an oral fluoropyrimidine) and oxaliplatin (a platinum-based cytotoxic agent). This triple combination was primarily evaluated in the Phase 2 RAINSTORM trial involving East Asian patients. However, the addition of ramucirumab to the standard SOX regimen did not demonstrate a significant improvement in progression-free survival or overall survival compared to SOX plus placebo, leading to the termination of its development for this specific first-line indication.
- Other names
- RAM+SOXramucirumab plus SOX
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on ramucirumab + S-1 + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramucirumab + S-1 + oxaliplatin.